Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluating Bronchodilator Response in Bronchiectasis
NCT05932316Unknown
- Sponsor
- Rambam Health Care Campus
- Start
- May 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in bronchiectasis, cystic fibrosis (CF), primary ciliary dyskinesia (PCD) and 2 more comparing Salbutamol first with Placebo First (2 arms). Primary endpoints: Bronchodilator response compared to placebo (change in FEV1) and Bronchodilator response compared to placebo (change in FVC). Status: unknown.
02
Drugs
salbutamol
03
Conditions
bronchiectasiscystic fibrosis (CF)primary ciliary dyskinesia (PCD)primary immunodeficiency (PI)Bronchiolitis Obliterans (BO)
Beyond the preview
Go deeper on NCT05932316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932316.